The promise of synthetic lethality in precision oncology
Kathryn L Chapman, Head of Discovery Biology & Jürgen Moll CSO at Tesselate Bio, explore alternative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomersin. Synthetic lethality and targeted drugs are a clinically established approach Synthetic lethality (SL) is an established, clinical and commercial approach… Read More